These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 24781280

  • 1. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
    Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Br J Cancer; 2014 May 27; 110(11):2669-76. PubMed ID: 24781280
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 3. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2019 Mar 15; 136():120-130. PubMed ID: 30660696
    [Abstract] [Full Text] [Related]

  • 4. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
    Wang Y, Sparidans RW, Wang J, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2022 Jan 15; 170():197-207. PubMed ID: 34952136
    [Abstract] [Full Text] [Related]

  • 5. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
    Loos NHC, Martins MLF, de Jong D, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Int J Pharm; 2024 Jan 25; 650():123708. PubMed ID: 38135258
    [Abstract] [Full Text] [Related]

  • 6. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.
    Loos NHC, Bui V, de Jong DH, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Cancer Chemother Pharmacol; 2024 Jul 25; 94(1):79-87. PubMed ID: 38456955
    [Abstract] [Full Text] [Related]

  • 7. Taxanes: old drugs, new oral formulations.
    Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH.
    Eur J Pharmacol; 2013 Oct 05; 717(1-3):40-6. PubMed ID: 23660368
    [Abstract] [Full Text] [Related]

  • 8. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.
    Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642
    [Abstract] [Full Text] [Related]

  • 9. Oral delivery of taxanes.
    Malingré MM, Beijnen JH, Schellens JH.
    Invest New Drugs; 2001 May 01; 19(2):155-62. PubMed ID: 11392449
    [Abstract] [Full Text] [Related]

  • 10. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
    Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A.
    J Cancer Res Clin Oncol; 2008 May 01; 134(5):597-607. PubMed ID: 17932689
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
    Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD.
    Br J Clin Pharmacol; 2010 May 01; 69(5):465-74. PubMed ID: 20573082
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K, Taniyama K, Aoyama T, Watanabe Y.
    Eur J Drug Metab Pharmacokinet; 2020 Jun 01; 45(3):385-392. PubMed ID: 32078103
    [Abstract] [Full Text] [Related]

  • 13. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
    Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH.
    Clin Cancer Res; 2009 Jun 15; 15(12):4228-33. PubMed ID: 19509162
    [Abstract] [Full Text] [Related]

  • 14. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
    Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O.
    Eur J Cancer; 2004 May 15; 40(8):1269-74. PubMed ID: 15110893
    [Abstract] [Full Text] [Related]

  • 15. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.
    Drug Metab Lett; 2012 Jun 01; 6(2):134-44. PubMed ID: 23061481
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
    Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB.
    Br J Clin Pharmacol; 2017 Apr 01; 83(4):927-930. PubMed ID: 27868228
    [Abstract] [Full Text] [Related]

  • 17. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.
    Koolen SL, Beijnen JH, Schellens JH.
    Clin Pharmacol Ther; 2010 Jan 01; 87(1):126-9. PubMed ID: 19924122
    [Abstract] [Full Text] [Related]

  • 18. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
    Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR.
    J Clin Pharmacol; 2020 Mar 01; 60(3):340-350. PubMed ID: 31595980
    [Abstract] [Full Text] [Related]

  • 19. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
    Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP.
    Drug Deliv; 2012 Nov 01; 19(8):363-70. PubMed ID: 23030458
    [Abstract] [Full Text] [Related]

  • 20. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.